Kpcb Xv Associates 13F annual report
Kpcb Xv Associates is an investment fund managing more than $35.8 million ran by Susan Biglieri. There are currently 3 companies in Mrs. Biglieri’s portfolio. The largest investments include RAPT Therapeutics and Twilio Inc, together worth $28.7 million.
$35.8 million Assets Under Management (AUM)
As of 19th October 2022, Kpcb Xv Associates’s top holding is 648,531 shares of RAPT Therapeutics currently worth over $15.6 million and making up 43.5% of the portfolio value.
Relative to the number of outstanding shares of RAPT Therapeutics, Kpcb Xv Associates owns more than approximately 0.1% of the company.
In addition, the fund holds 190,047 shares of Twilio Inc worth $13.1 million, whose value fell 36.2% in the past six months.
The third-largest holding is Atara Biotherapeutics Inc worth $7.09 million.
Currently, Kpcb Xv Associates's portfolio is worth at least $35.8 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Kpcb Xv Associates
The Kpcb Xv Associates office and employees reside in Menlo Park, California. According to the last 13-F report filed with the SEC, Susan Biglieri serves as the Attorney-in-Fact at Kpcb Xv Associates.
Recent trades
There are companies that Kpcb Xv Associates is getting rid of from its portfolio.
Kpcb Xv Associates closed its position in Augmedix, Inc. on 26th October 2022.
It sold the previously owned 708 shares for $1 thousand.
Susan Biglieri also disclosed a decreased stake in RAPT Therapeutics by 0.5%.
This leaves the value of the investment at $15.6 million and 648,531 shares.
One of the smallest hedge funds
The two most similar investment funds to Kpcb Xv Associates are Camelot Capital Partners and Tappan Street Partners. They manage $35.8 million and $35.7 million respectively.
Susan Biglieri investment strategy
Kpcb Xv Associates’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 63.3% of
the total portfolio value.
The fund focuses on investments in the United States as
100.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
33% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $4.96 billion.
The complete list of Kpcb Xv Associates trades based on 13F SEC filings
These positions were updated on October 26th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| RAPT Therapeutics, Inc. |
50.00%
648,531
|
$15,604,000 | 43.54% |
| Twilio Inc |
No change
190,047
|
$13,140,000 | 36.66% |
| Atara Biotherapeutics Inc |
No change
1,876,650
|
$7,094,000 | 19.79% |
| Augmedix, Inc. |
Closed
708
|
$1,000 | |
| No transactions found | |||
| Showing first 500 out of 4 holdings | |||
Hedge funds similar to Kpcb Xv Associates
- Kiron Capital Gestao De Recursos Ltda
- Ponoi Ii Management
- Cincinnati Indemnity Co
- Ug Investment Advisers
- Essex Private Wealth Management
- Florin Court Capital LL.P.
- Fsa Wealth Management
- Ab Carval Investors, L.P.
- Camelot Capital Partners
- Tappan Street Partners
- Kpcb Xii Associates
- Aetna Inc pa/
- Lightspeed Ultimate General Partner Ix
- Opportunities Capital Management